Amarin Corp Plc (AMRN)

[sts66]

AMRN didn't use the regression to the mean explanation? That one is so obvious I can't believe they didn't mention it - and they did mention it multiple times in their BD's - like this bit:

If placebo were assumed to have a hypothetical negative impact on LDL-C or other biomarkers
(to which we do not agree nor sees evidence of this occurring), these analyses suggest the
biomarker changes observed in the REDUCE-IT placebo arm could have at most translated to a
small (-0.019 to +0.036) hypothetical impact on outcomes. To the contrary, based on detailed
evaluation and assessment of available data, the totality of evidence leads to the conclusion that
the changes in biomarker levels from baseline observed in REDUCE-IT were most likely due to
regression to the mean, disease progression, and other underlying phenomena, and not due to
placebo-mediated effects.